Board approves Right Issue
Neuland Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 05, 2014, inter alia, has approved the following:1. Issue of equity shares on Rights basis to the members of the Company not exceeding Rs. 25 crores.2. Constitution of a sub-committee called the Rights Issue Committee to finalize the Rights ratio, issue price, record date and all other matters relating the proposed Rights Issue. Financial Results & Limited Review for Dec 31, 2013
Neuland Laboratories Ltd has informed BSE about the Financial Results & a copy of the Limited Review Report for the period ended December 31, 2013. Board to consider Right Issue
Neuland Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 05, 2014, inter alia, to consider the issue of equity shares on rights basis to the members of the Company, along with the unaudited financial results for the quarter ended December 31, 2013. Closure of Trading Window
Neuland Laboratories Ltd has informed BSE that a meeting of Board of Directors of the Company will be held on February 05, 2014, inter alia, to consider and take on record the unaudited financial results of the Company for the quarter ended December 31, 2013.Further, as per the provisions of the Code of Conduct for Prevention of Insider Trading of the Company, the Trading Window for transactions in shares of the Company is closed from January... Allotment of Equity Shares to employees under Employee Stock Option Scheme, 2008
Neuland Laboratories Ltd has informed BSE that the Board of Directors on January 21, 2014, had allotted 10,700 fully paid up equity shares of a face value of Rs. 10 each, to eligible employees pursuant to exercise of stock options granted under Employee Stock Option Scheme, 2008.Consequently w.e.f. January 21, 2014, the paid-up equity capital of the Company stands increased to Rs. 7,65,56,780 from Rs. 7,64,49,780. Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Neuland Laboratories Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992 Disclosures under Reg.13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Neuland Health Sciences Pvt Ltd has submitted the disclosure under Regulation 13(4A) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 to BSE Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Neuland Laboratories Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992 Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Neuland Laboratories Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992 Disclosures under Reg.13(4), 13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992
S B Budhiraja & S B Budhiraja HUF has submitted the disclosures under Reg.13(4), 13(4A) of SEBI (Prohibition of Insider Trading) Regulations, 1992